InterWest Partners

Bruker said this week it has appointed Joshua Young vice president of investor relations. Young will take over from Stacey Desrochers, who will focus on management of the company's treasury operations.

The company next year plans to launch a 1,000-patient verification trial for its lung cancer protein biomarker panel, with trials for its Alzheimer's disease panel likely to follow, said an official.

The molecular diagnostics company plans to use the funds for marketing and R&D.

Lycera, which is developing drugs for autoimmune diseases, will use the cash to advance through Phase II proof-of-concept studies a drug based on University of Michigan research, and into Phase I trials a second candidate based on research conducted at New York University.

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

In Nature this week: ash dieback disease fungal genome, and more.